Beximco Pharmaceuticals PLC. Stock London S.E.
Stocks
BXP
US0885792061
Pharmaceuticals
OTC Markets Traded|
Market Closed -
London S.E.
11:35:06 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 56.00 GBX | +1.82% |
|
+6.67% | +31.76% |
| 06-26 | Beximco suspension lifted; M1 payment date extension | AN |
| 06-24 | Beximco Pharmaceuticals PLC. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 | CI |
| Market Cap | 65.8B 536M 463M 435M 396M 744M 51.27B 756M 5.1B 1.99B 25.67B 2.01B 1.97B 85.32B | P/E 2026 * |
7.6x | P/E 2027 * | 6.9x |
|---|---|---|---|---|---|
| Enterprise Value | 65.8B 536M 463M 435M 396M 744M 51.27B 756M 5.1B 1.99B 25.67B 2.01B 1.97B 85.32B | EV / Sales 2026 * |
1.2x | EV / Sales 2027 * | 1.08x |
| Free-Float |
85.91% | Yield 2026 * |
4.08% | Yield 2027 * | 5.22% |
| 1 day | +1.82% | ||
| 1 week | +6.67% | ||
| Current month | +8.74% | ||
| 1 month | +5.66% | ||
| 3 months | +31.76% | ||
| 6 months | +31.76% | ||
| Current year | +31.76% |
| 1 week | 52 |  | 56.7 |
| 1 month | 49.55 | | 56.7 |
| Current year | 39.5 | | 57 |
| 1 year | 36.7 | | 57 |
| 3 years | 19.32 | | 57 |
| 5 years | 19.32 | | 131 |
| 10 years | 19.32 | | 131 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iqbal Ahmed
CEO | Chief Executive Officer | - | 2024-03-03 |
| Director of Finance/CFO | 63 | 2002-12-31 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 2009-06-18 | |
| Director/Board Member | - | 2010-01-31 | |
Iqbal Ahmed
BRD | Director/Board Member | - | 1984-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.82% | +6.67% | - | - | 537M | |
| -2.25% | -0.47% | +68.30% | +116.05% | 1,052B | |
| -0.66% | +0.43% | +47.39% | +51.02% | 627B | |
| -0.54% | +1.39% | +20.69% | +64.61% | 441B | |
| -1.99% | -3.32% | +38.71% | +36.26% | 349B | |
| -1.05% | -2.81% | +23.07% | +35.91% | 287B | |
| -2.12% | -3.67% | -1.14% | +5.35% | 241B | |
| -0.63% | +1.04% | +40.05% | +56.67% | 224B | |
| -1.19% | -3.41% | -9.57% | -53.50% | 202B | |
| +0.16% | +3.87% | +16.89% | +77.38% | 172B | |
| Average | -0.84% | +0.26% | +27.15% | +43.31% | 399.46B | |
| Weighted average by Cap. | -1.36% | +0.04% | +39.09% | +61.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54.78B 446M 386M 362M 329M 619M 42.68B 630M 4.25B 1.66B 21.38B 1.68B 1.64B 71.03B | 60.95B 497M 429M 403M 367M 689M 47.49B 701M 4.72B 1.85B 23.78B 1.86B 1.82B 79.03B |
| Net income | 8.66B 70.58M 60.96M 57.28M 52.1M 97.95M 6.75B 99.56M 671M 262M 3.38B 265M 259M 11.23B | 9.52B 77.6M 67.03M 62.98M 57.28M 108M 7.42B 109M 738M 289M 3.72B 291M 285M 12.35B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-14 | GBX 56.00 | +1.82% | 40,346 |
| 26-08-13 | GBX 55.00 | -1.79% | 2,516 |
| 26-08-12 | GBX 56.00 | +1.82% | 1,187 |
| 26-08-11 | GBX 55.00 | +4.76% | 121,546 |
| 26-08-10 | GBX 52.50 | 0.00% | 50,766 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BXPHARMA Stock
- BXP Stock
Select your edition
All financial news and data tailored to specific country editions
